Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Tumor Biology.
2015,
36(6),
4243-52,
ISSN: 1010-4283,
PMID: 25616695,